AKAlesia Kaplan

Alesia Kaplan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alesia Kaplan has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    How do we maintain a dual inventory of room temperature stored platelets with cold‐stored platelets?

    by Claudia S. Cohn, Nancy M. Dunbar, Alesia Kaplan, Philip C. Spinella, Pampee P. Young, Alyssa Ziman

    Background: There has been renewed interest in cold‐stored platelets (CSPs) for the management of bleeding patients. CSPs might offer advantages over conventional room temperature stored platelet units (RTP), such as a lower risk of bacterial growth during storage, a longer shelf lf life, and possibly improved hemostatic effectiveness. However, CSPs have reduced in vivo survival compared to RTP. In 2023, the FDA issued guidance allowing 14‐day storage of CSPs for the treatment of active bleeding when conventional platelets are not available or their use is not practical. This How Do We describes various scenarios of CSP use, followed by the authors' assessment regarding consistency with FDA recommendations.Methods: The authors contributed scenarios that reflected their institutions' unique settings or more generalized scenarios common to other centers. The authors offered their interpretation of the guidance for each specific situation.Results: Seven scenarios are provided that demonstrate potentially appropriate or clearly inappropriate CSP use across a variety of settings. The authors' interpretations aim to help hospital transfusion services develop standard operating procedures (SOPs) that are suitable for their own unique circumstances.Discussion: Each hospital has a unique setting and set of conditions that influence CSP use. This How Do We provides the authors' assessments regarding how CSPs may be used in certain scenarios; however, this is not a guide and does not offer official recommendations. Every center must develop SOPs that account for usage patterns and inventory constraints specific to its own environment.


  • Prophylactic high‐dose granulocyte transfusions following allogeneic haematopoietic stem cell transplantation

    by Yannis Hadjiyannis, Robert Bubar, Darrell J. Triulzi, Joseph Kiss, Christopher C. Marino, Randy M. Windreich, Paul Szabolcs, Alesia Kaplan

    Background and Objectives: Prophylactic granulocyte transfusions (PGTxs) are controversial. Previous studies faced numerous confounders such as achieving an adequate dose. Pre‐emptive or secondary PGTx for persistent, severe pre‐transplant infections has rarely been reported for patients undergoing haematopoietic stem cell transplantation (HSCT). Here, we reviewed the feasibility, safety and implementation of high‐dose PGTx in high‐risk patients undergoing HSCT with a history of persistent, recurrent infections.Materials and Methods: We conducted a retrospective review (2018–2021) for all HSCT patients who received high‐dose PGTx from donors stimulated with granulocyte colony‐stimulating factor and dexamethasone at our tertiary medical centre. PGTx was carried out as secondary prophylaxis to prevent infection recurrence/progression.Results: Seven patients received PGTx during HSCT; 95% of all transfused products contained a dose ≥0.6 × 109/kg. Post‐transfusion absolute neutrophil count (ANC) showed an average increase of 5.5 ± 3.7 × 109/L. All PGTxs were well tolerated, with no evident transfusion reactions, adverse effects or human leukocyte antigen alloimmunization. A high overall survival rate (100% at day 30), afebrile rate (85%) and absence of infections were noted.Conclusion: Optimized high‐dose PGTx resulted in a measurable ANC increase and was well tolerated. Although efficacy and safety remain to be established, we highlight the ability to produce and implement optimized high‐dose PGTx for high‐risk patients undergoing HSCT.


  • Optimized high‐dose granulocyte transfusions for the treatment of infections in neutropenic patients: A single‐center retrospective analysis

    by Yannis Hadjiyannis, Robert Bubar, Darrell J. Triulzi, Joseph Kiss, Christopher C. Marino, Alesia Kaplan

    Background: Granulocyte transfusions for patients with prolonged neutropenia and severe infections has been a controversial practice. Previous studies suggest a benefit of high‐dose granulocyte transfusions (≥0.6 × 109/kg), although, until recently, the consistent production of high‐dose units has been challenging. Here, we present our experience and results utilizing high‐dose granulocyte transfusions at a large, tertiary academic medical center for the treatment of infections in adult, neutropenic patients.Study Design/Methods: A retrospective chart review (2018–2021) was conducted for all patients who received high‐dose granulocyte transfusions from donors stimulated with granulocyte colony‐stimulating factor (G‐CSF) and dexamethasone. Gathered parameters included patient demographics, clinical history, infection status, dose, clinical outcomes, pre‐ and post‐absolute neutrophil count (ANC), and transfusion times including time between granulocyte collection, administration, and posttransfusion ANC count. Gathered parameters were summarized using descriptive statistics, outcomes were assessed utilizing Kaplan–Meier curves/log‐rank/regression testing.Results: Totally 28 adult, neutropenic patients refractory to antimicrobial agents and/or G‐CSF received a total of 173 granulocyte concentrates. Median ANC increased from 0.7 × 109/L pre‐transfusion to 1.6 × 109/L posttransfusion. The mean granulocyte yield was 77.4 × 109 resulting in an average dose per kilogram of 0.90 × 109 ± 0.30 × 109 granulocytes. Composite day 42 survival and microbial response was 42.9% (n = 12/28) without significant adverse reactions.Discussion: Here, we demonstrate the successful and safe implementation of high‐dose granulocyte transfusions for neutropenic patients. Given the rapid and consistent production, distribution, and improved granulocyte quality, further investigations to determine the clinical efficacy of G‐CSF primed granulocyte transfusions is now possible.


  • Successful management of maternal anti‐PP1Pk alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin

    by Yannis Hadjiyannis, Jennifer M. Jones, Irina Chibisov, Joseph Kiss, Kim Gabert, Joan Sevcik, Suzanne Bakdash, Anna Binstock, Carolyn Kilonsky, Kristiina Parviainen, et al.

    Anti‐PP1PK alloimmunization is rare given ubiquitous P1PK expression. Prevention of recurrent miscarriages and hemolytic disease of the fetus and newborn (HDFN) in pregnant individuals with anti‐PP1PK antibodies has relied upon individual reports. Here, we demonstrate the successful management of maternal anti‐PP1PK alloimmunization in a 23‐year‐old, G2P0010, with therapeutic plasma exchange (TPE), intravenous immunoglobulin (IVIG), and monitoring of anti‐PP1Pk titers. Twice‐weekly TPE (1.5 plasma volume [PV], 5% albumin replacement) with weekly titers and IVIG (1 g/kg) was initiated at 9 weeks of gestation (WG). The threshold titer was ≥16. Weekly middle cerebral artery‐peak systolic velocities (MCA‐PSV) for fetal anemia monitoring was initiated at 16 WG. PVs were adjusted throughout pregnancy based on treatment schedule, titers, and available albumin. Antigen‐negative, ABO‐compatible RBCs were obtained through the rare donor program and directed donation. An autologous blood autotransfusion system was reserved for delivery. Titers decreased from 128 to 8 by 10 WG. MCA‐PSV remained stable. At 24 WG, TPE decreased to once weekly. After titers increased to 32, twice‐weekly TPE resumed at 27 WG. Induction of labor was scheduled at 38 WG. Vaginal delivery of a 2950 g neonate (APGAR score: 9, 9) occurred without complication (Cord blood: 1+ IgG DAT; Anti‐PP1Pk eluted). Newborn hemoglobin and bilirubin were unremarkable. Discharge occurred postpartum day 2. Anti‐PP1Pk alloimmunization is rare but associated with recurrent miscarriages and HDFN. With multidisciplinary care, a successful pregnancy is possible with IVIG and TPE adjusted to PV and titers. We also propose a patient registry and comprehensive management plan.


  • Effective peripheral blood stem cell collection in a 4.6‐kg child

    by Jennifer M. Jones, Joseph E. Kiss, Irina Chibisov, Paulina Horvei, Heather Stanczak, Carol Burda, Wei Clark, Joan Sevcik, Carolyn Kilonsky, Alesia Kaplan

    Background: Due to unique technical challenges, effective peripheral blood stem cell collections (PBSCs) have not been consistently reported in patients weighing less than 5 kg. We describe three PBSCs performed in a 4.6‐kg child undergoing myeloablative chemotherapy for high‐grade glioma.Study Design and Methods: A multidisciplinary group representing the clinical and apheresis teams adapted a PBSC protocol to accommodate the patient's size and collection targets. Special considerations included timing of the collection relative to chemotherapy, vascular access, strategies for monitoring adverse events during collection, and contingencies.Results and Discussion: The patient underwent three PBSC procedures over 2 days due to suboptimal collection after the first two procedures. For procedure 1, a conservative inlet: anticoagulant (AC) ratio and AC infusion rate of 15 and 0.6 mL/min/L total blood volume (TBV) resulted in premature discontinuation due to clotting. A ratio of 8 and AC infusion rate of 1.5–1.7 mL/min/L TBV with subsequent titration to higher levels were adopted for the second and third procedures. These changes resulted in greater acid‐citrate‐dextrose exposure, that was managed by continuous calcium chloride infusion. There was no hypocalcemia, hypotension, or distress during any procedure. A total of 15 × 106 CD34+ cells/kg were collected. This retrospective review illustrates that PBSC can be safely undertaken in children weighing less than 5 kg.


  • Open Access

    Evaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial

    by Edward L. Snyder, Michael E. Sekela, Ian J. Welsby, Yoshiya Toyoda, Mohamed Alsammak, Neel R. Sodha, Thomas M. Beaver, J. Peter R. Pelletier, Alesia Kaplan, Roman M. Sniecinski, et al.

    Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, emerging viruses, pathogens for which testing is not performed and from residual donor leukocytes. Amustaline (S-303)/glutathione (GSH) treatment pathogen reduction technology is designed to inactivate a broad spectrum of infectious agents and leucocytes in RBC concentrates. The ReCePI study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of pathogen reduced RBCs transfused for acute anemia in CVS compared to conventional RBCs, and to assess the clinical significance of treatment-emergent RBC antibodies. Methods ReCePI is a prospective, multicenter, randomized, double-blinded, active-controlled, paralleldesign, non-inferiority study. Eligible subjects will be randomized up to 7 days before surgery to receive either leukoreduced Test (pathogen reduced) or Control (conventional) RBCs from surgery up to Day 7 post-surgery. The primary efficacy endpoint is the proportion of patients transfused with at least one study transfusion with an acute kidney injury (AKI) diagnosis defined as any increased serum creatinine (sCr) level ≥0.3 mg/dL (or 26.5 µmol/L) from presurgery baseline within 48±4 hours of the end of surgery. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to pathogen reduced RBCs through 75 days after the last study transfusion. With ≥292 evaluable, transfused patients (>146 per arm), the study has 80% power to demonstrate non-inferiority, defined as a Test group AKI incidence increase of no more than 50% of the Control group rate, assuming a Control incidence of 30%. Discussion RBCs are transfused to prevent tissue hypoxia caused by surgery-induced bleeding and anemia. AKI is a sensitive indicator of renal hypoxia and a novel endpoint for assessing RBC efficacy. The ReCePI study is intended to demonstrate the non-inferiority of pathogen reduced RBCs to conventional RBCs in the support of renal tissue oxygenation due to acute anemia and to characterize the incidence of treatment-related antibodies to RBC.

  • Open Access

    Not as “D”eadly as once thought – the risk of D-alloimmunization and hemolytic disease of the fetus and newborn following RhD-positive transfusion in trauma

    by Mark H. Yazer, Gleb Panko, John B. Holcomb, Alesia Kaplan, Christine Leeper, Jansen N. Seheult, Darrell J. Triulzi, Philip C. Spinella

    The use of blood products to resuscitate injured and massively bleeding patients in the prehospital and early in-hospital phase of the resuscitation is increasing. Using group O red blood cells (RBC) and low titer group O whole blood (LTOWB) avoids an immediate hemolytic reaction from recipient’s naturally occurring anti-A and – B, but choosing the RhD type for these products is more nuanced and requires the balancing of product availability and survival benefit against the risk of D-alloimmunization, especially in females of childbearing potential (FCP) due to the possible future occurrence of hemolytic disease of the fetus and newborn (HDFN). Recent models have estimated the risk of fetal/neonatal death from HDFN resulting from D-alloimmunization of an FCP during her trauma resuscitation at between 0-6.5% depending on her age at the time of the transfusion and other societal factors including trauma mortality, her age when she becomes pregnant, frequency of different RHD genotypes in the population, and the probability that the woman will have children with different fathers; this is counterbalanced by an approximately 24% risk of death from hemorrhagic shock. This review will discuss the different models of HDFN outcomes following RhD-positive transfusion as well as the results of recent surveys where the public was asked about their preferences for urgent transfusion in light of the risks of fetal/neonatal adverse events.


  • An unusual case of anti‐D detection in two consecutive D+ patient samples: Antibody carryover on an automated gel platform

    by Kimberly Gabert, Jansen N. Seheult, Michael P. Meyer, Darrell J. Triulzi, Alesia Kaplan

    Background: Laboratory results can be affected by sample to sample carryover. Carryover of different analytes occurring in automated clinical chemistry, immunology, hematology, and molecular laboratories is well described. However, carryover in a transfusion service laboratory is not reported in medical literature.Materials and methods: Immunohematology testing results, demographic data, and clinical data were reviewed on three patients retrospectively from 2015 to 2019.Results: Type and screen samples tested on automated gel platform from two D+ patients were affected by anti‐D carryover from a patient sample with a very high‐titer anti‐D. Additional immunohematology and molecular testing confirmed that anti‐D in samples of two D+ patients was due to carryover.Conclusion: A case of anti‐D carryover caused false detection of anti‐D in two D+ patients. Carryover can have implications for patient management. Transfusion laboratory staff need to be aware of it and investigate any unexpected results further.


  • Benchmarking the centralized urgent plasma exchange service for patients admitted with a diagnosis of suspected acquired thrombotic thrombocytopenic purpura at a large healthcare system

    by Jansen N. Seheult, Michelle N. Stram, Joan Sevcik, Alesia Kaplan, Joseph E. Kiss

    Background: Consensus guidelines recommend that therapeutic plasma exchange (TPE) should be started within 4 to 8 hours after the diagnosis of suspected acquired thrombotic thrombocytopenic purpura (aTTP). This study aimed to audit the steps from diagnosis to initiation of plasma exchange at a centralized apheresis service.Methods: A retrospective review of the electronic medical record and laboratory information systems from January 1, 2014 to August 31, 2017 was conducted to identify all patients with suspected aTTP undergoing TPE. Demographics, comorbidities, pertinent laboratory tests, and temporal TPE procedural data were collected.Results: The median (5th‐95th percentile) time from request to initiation of TPE was 5.4 (3.2‐10.6) hours. TPE was initiated within 8 hours in 94 of the 108 patients (87.0%). The median (5th‐95th percentile) time from request to central venous access was 2.5 (0.5‐6.9) hours and from request to plasma product issuance from the blood bank was 3.4 (1.6‐8.1) hours. aTTP patients in whom TPE was initiated greater than 6 hours from request did not have worse outcomes compared to those with TPE initiation within 6 hours: in‐hospital mortality (2/14 [14.3%] vs 2/21 [9.5%], P = 0.66), median length of stay (9.0 [4.7‐44.1] vs 8.3 [3.9‐27.0] days, P = 0.76), and median number of days to durable platelet count recovery (4.5 [2.0‐9.0] vs 4.0 [2.0‐18.0] days, P = 0.66).Conclusions: The 4 to 8‐hour target window from TPE request to initiation appears feasible for a centralized apheresis program servicing a large healthcare system.